Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.76 |
| ▸ | CTSK | P43235 | 6/20 | 0.76 |
| ▸ | CTSL | P07711 | 3/20 | 0.76 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999046 | 1.00 | CTSS (0.76) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL29828648 | 1.00 | CTSS (0.76) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL29908025 | 1.00 | CTSS (0.76) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL3599165 | 1.00 | CTSS (0.76) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL8968483 | 0.94 | CTSS (0.68) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL9001355 | 0.90 | CTSS (0.71) | CTSSCTSKCTSLSCN9ATACR1 | |
| SCHEMBL29828668 | 0.90 | CTSS (0.71) | CTSSCTSKCTSLSCN9ATACR1 | |
| SCHEMBL5861615 | 0.89 | CTSS (0.62) | CTSSCTSKCTSLACESCN9A | |
| SCHEMBL5556628 | 0.89 | CTSS (0.76) | CTSSCTSKCTSLTACR1CTSB | |
| SCHEMBL19203445 | 0.87 | CTSL (0.65) | CTSSCTSKCTSLACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | disclosed |
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP. | 2017-08-03 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| EP-1932853-A1 | Novel depsipeptides and process for preparing same | Cubist Pharmaceutical Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-0828754-B1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0828754-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5612336-A | Heterocyclic amide derivatives as tachykinin antagonists | MERCK, SHARP & DOHME LTD. (GB) | 1997-03-18 | — | — | US | disclosed |
| WO-1996038471-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5514718-A | AMINO COMPOUNDS WITH ALKOXY, HYDROXY, KETONE OR OXIME GROUPS FOR PSYCHOLOGICAL DISORDERS OR TACHYKININ ANTAGONIST | MERCK, SHARP & DOHME LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| US-5328927-A | Tachykinin antagonists | MERCK SHARPE & DOHME, LTD. (GB) | 1994-07-12 | — | — | US | disclosed |
| WO-1994001402-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS TACHYKININ DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | CTSS 4527/4885CTSK 4550/4885CTSL 1982/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | CTSS 4527/4885CTSK 4550/4885CTSL 1982/4885 |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | CTSS 4527/4885CTSK 4550/4885CTSL 1982/4885 |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | CTSS 379/4885CTSK 780/4885CTSL 309/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | CTSS 1297/4885CTSK 2606/4885CTSL 3033/4885 |
| US-10202353-B2 | Therapeutic compounds | RPL35, SARS1, HAVCR2 | CTSS 436/4885CTSK 782/4885CTSL 379/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | CTSS 2636/4885CTSK 1778/4885CTSL 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.